Trial Profile
A Randomized Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 + Ezetimibe 10 Fixed-Dose Combination Compared to Ezetimibe and Placebo In Subjects With T2DM and Elevated LDL-Cholesterol
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Bempedoic acid/ezetimibe (Primary) ; Ezetimibe
- Indications Hypercholesterolaemia; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 30 Mar 2020 Results (n=179) presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
- 30 Mar 2020 Results presented in a Daiichi Sankyo Europe media release.
- 28 Mar 2020 According to a Esperion AB media release, results from this trial were presented at the at the American College of Cardiology's 69th Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) on March 28th-30th 2020.